Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

26.70 +0.41 (+1.56%)

Streaming Delayed Price Updated: 12:51 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Acadia Announces Additions to Executive Team

January 30, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals ↗

January 24, 2024

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

January 18, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Deep Dive Into ACADIA Pharmaceuticals Stock: Analyst Perspectives (13 Ratings) ↗

December 29, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

December 12, 2023

Via Benzinga

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

November 06, 2023

Via Benzinga

Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

December 21, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 18, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)

December 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Analyst Ratings for ACADIA Pharmaceuticals ↗

October 10, 2023

Via Benzinga

Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug ↗

December 13, 2023

MSN Labs lost out in a summary judgement to knock off Acadia's Nuplazid.

Via Investor's Business Daily

Topics Intellectual Property

Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation

December 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

What's Going On With Acadia Pharmaceuticals Stock? ↗

December 13, 2023

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know:

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 13, 2023

Via Benzinga

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Leading the Way in Wednesday Trading Based on Percentage Gain

December 13, 2023

Via Investor Brand Network

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

December 11, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

November 30, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis

November 27, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

November 21, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 14, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

Via InvestorPlace

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

November 02, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 02, 2023

Via Benzinga

Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference

October 31, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program

October 23, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023

October 19, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 18, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.